{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-273393","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.017169+00:00","generated_at":"2026-05-29T05:39:50.873738+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cogent Biosciences reports positive Phase 2 bezuclastinib data in AdvSM and NonAdvSM at ASH 2024","bullets":["APEX (AdvSM): 52% ORR per mIWG-MRT-ECNM; 61% in TKI-naïve; 83% at 100 mg BID. Median PFS not reached; 24-mo PFS rate 82%.","100% PPR ORR at 100 mg BID; 94% of patients had >=50% tryptase reduction; 93% had >=50% KIT D816V VAF reduction.","SUMMIT (NonAdvSM): 56% mean TSS improvement; 76% of patients had >50% MS2D2 reduction; 49% mean MC-QoL improvement at 24 wks.","95% of patients with baseline tryptase >=20 ng/mL achieved <20 ng/mL by week 24; 84% with baseline >11.4 ng/mL achieved <11.4.","SUMMIT Part 2 enrollment complete (179 patients); top-line expected July 2025. APEX Part 2 enrollment completion Q1 2025; top-line mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-273393","json":"https://secwatch.observer/filing/0001193125-24-273393.json","markdown":"https://secwatch.observer/filing/0001193125-24-273393.md","text":"https://secwatch.observer/filing/0001193125-24-273393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524273393/0001193125-24-273393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524273393/d914555d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:39:50.873738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}